LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan Designation for ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of primary large B-Cell lymphomas of immune-privileged sites, including primary vitreoretinal lymphoma. There is currently no approved treatment for patients with primary vitreoretinal lymphoma, a rare, aggressive, high-grade cancer that affects appr
Related Questions
What are the anticipated timelines for further clinical development and potential FDA/EMA approval of ADX‑2191 following the orphan designation?
How large is the addressable market for primary vitreoretinal lymphoma and what revenue upside could this orphan designation create for Aldeyra?
Will securing orphan status affect Aldeyra’s financing strategy, such as dilution risk from future equity raises or eligibility for orphan‑drug incentives?